Clinical Research Directory

Inclusion Criteria: * Patients with non-segmental vitiligo. * Patients with stable vitiligo for at least 6 months based on the Vitiligo Disease Activity (VIDA) score. * Aged 10-17 years. * Affected area \<10%. * Having at least two lesions to be treated. The vitiligo lesions selected for treatment must meet the following criteria: 1. Relatively the same size, ranging from a minimum of 1 cm² to 4 cm². 2. Bilateral location on both sides of the body. 3. A minimum distance of 5 cm between the studied lesions and other vitiligo lesions. 4. Not located on the palms, soles, or genital area. Exclusion Criteria: * Use of topical therapy (corticosteroids, calcineurin inhibitors, psoralen, and antioxidants) for at least 2 weeks before the study, systemic therapy (corticosteroids, antioxidants, and vitamin D) for at least 4 weeks before the study, and phototherapy for at least 4 weeks before the study. * Presence of other active autoimmune diseases such as type 1 diabetes mellitus, thyroid disease, alopecia areata, rheumatoid arthritis, or Addison's disease, based on medical history and physical examination. * History of or current skin cancer, photosensitivity, or undergoing radiotherapy. * Allergy or contraindication to topical corticosteroids or latanoprost. * History of hypertension, asthma, diabetes mellitus, anemia, kidney, liver, neurological, or cardiovascular diseases.